Subscribe

Shitanshu Uppal

LARA: Pembrolizumab plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma

Pembrolizumab plus lenvatinib demonstrated promising anti-tumor activity with an objective response rate of 40% at 24 weeks in patients with recurrent gynaecological clear cell carcinoma.

GOG 3026: Ribociclib Plus Letrozole in Recurrent Low-Grade Serous Ovarian Carcinoma

Publications Update # 128

How to form and break habits, MMR deficiency, MLH1 promoter hypermethylation, and outcomes, low-grade serous ovarian cancer 3026 trial, and FOLR1 expression in low-grade serous ovarian cancer. Updated video of neuroendocrine tumors.

Publications Update # 127

PORTEC 4A video summary and study summary, management of cancer in pregnancy, Mirvetuximab and occular side effects in real world setting and GYOEDU Launchpad details

Test Portal For LMS

Simple Laparoscopic Hysterectomy Tutorial

Laparoscopic Hysterectomy Video

Publications Update # 126

Kintsugi, the art of joining pottery, gyoedu search function update, mock oral dates released, KELIM score to decide who gets HIPEC, Compass study - nab-paclitaxel vs paclitaxel in platinum resisant ovarian cancer, ROSELLA trial Quiz, FZOCUS study

Publications Update # 125

Walk around the world, video tutorial - gastric type adenocarcinomas of the cervix, time to surgery - does it matter in ovarian cancer, pembrolizumab and lenvatinib in carcinosarcoma

Publications Update # 124

John Green's NYT interview, practical tips on how to integrate exercise in cancer treatment, dual PD-1 and CTLA-4 inhibition in MMRd/MSI cancers, video tutorial on cardiac toxicity of Immune Checkpoint inhibitors

Publications Update # 123

Joy/HBR; Sutures, needles & knots; Radiation shielding in pregnancy; MIS in UPSC; GYOEDU non-sloppy MIS guide; GYN residency proposal; Surgical leadership; Elite tennis training for surgeons.